ImmuCell Corporation (ICCC) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals: improved gross margins and domestic sales growth are positive, but supply constraints, competition, and declining international sales offset this. The Q&A reveals management's evasiveness on recurring revenue, raising concerns. Despite operational improvements and no large future write-downs, the lack of guidance on recurring revenue and international market underdevelopment tempers optimism. The neutral sentiment reflects these balanced positives and negatives, with no strong catalysts to drive significant stock movement.
Key Financial Performance
Total Product Sales (2025) $27.6 million, a 4.3% increase compared to 2024. This growth was driven by increased domestic sales and a shift towards higher-priced products like Tri-Shield, despite a decrease in international sales due to order timing from the Canadian distributor.
Net Operating Profit (2025) $1.6 million, an improvement of $3.3 million compared to 2024. This was largely driven by significantly expanded gross margins.
Product Sales (Q4 2025) $7.6 million, a decrease of 1.6% compared to Q4 2024. The decline was attributed to strong Q4 2024 sales benefiting from increased demand and catching up from a prior backorder situation.
Domestic Sales (Q4 2025) $7 million, an 8.7% increase compared to Q4 2024. This growth was offset by a decline in international sales.
International Sales (Q4 2025) $600,000, a decline of more than 50% compared to Q4 2024, mainly driven by order timing in Canada.
Gross Margin (2025) 41%, an increase from 30% in 2024. This improvement was driven by increased manufacturing volumes, efficiencies, and product price increases, partially offset by noncash inventory write-downs.
Gross Margin (Q4 2025) 38%, an increase from 37% in Q4 2024, despite being suppressed by noncash inventory write-downs.
Noncash Inventory Write-Downs (2025) $650,000, approximately 2.4% of full-year revenue and 5.9% of Q4 revenue. This was part of a thorough review of fixed assets and inventories.
Operating Expenses (2025) $9.8 million, an increase from $9.6 million in 2024. The increase was primarily driven by higher G&A expenses, partially offset by reductions in product development expenses related to Re-Tain.
Other Expense (2025) $2.7 million, an increase from $500,000 in 2024. This was primarily due to a noncash write-down impairment charge of $2.7 million for Re-Tain-related property, plant, and equipment.
Net Loss (2025) $1 million, a $1.1 million improvement compared to 2024. This improvement was driven by higher sales and increased gross margins, despite the significant impact of the $2.7 million Re-Tain write-down.
Basic Net Loss Per Share (2025) $0.12 per share, compared to a net loss of $0.26 per share in 2024.
Operating Income (2025) $1.6 million, compared to an operating loss of $1.6 million in 2024, representing a year-over-year improvement of $3.3 million.
Cash on Hand (End of 2025) $3.8 million, with working capital increasing from $10.6 million at the end of 2024 to $13 million at the end of 2025, driven by higher finished goods inventory.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
First Defense product line: Shifted strategy to focus on the First Defense franchise, which is a preventative solution for calf scours. The product is colostrum-derived, USDA-approved, and provides superior protection against pathogens compared to competitors.
Manufacturing capacity: Increased manufacturing capacity from 3 million units in 2023 to 4.6 million units in 2025, with plans to further increase capacity to 5-6 million units per year.
Market share growth: Captured 15% share of treated calves in the U.S. in 2025, up from 10% eight years ago. Gained revenue share against larger competitors despite prior supply constraints.
Market opportunity: The U.S. calf scours prevention market is valued at $93 million in 2025, with a total addressable market exceeding $200 million. International market potential is at least 5x larger.
Gross margin improvement: Gross margin increased to 41% in 2025 from 30% in 2024, driven by higher manufacturing volumes, efficiencies, and price increases.
Financial performance: Achieved $27.6 million in product sales and $1.6 million in operating profit in 2025, a $3.3 million improvement compared to 2024.
Strategic shift: Paused investment in subclinical mastitis product to focus on First Defense and manufacturing improvements.
Sales expansion: Hired a senior international market development leader, a new U.S. sales manager, and are recruiting additional commercial positions to expand sales capacity.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Quarterly Sales Decline: Product sales for Q4 2025 decreased by 1.6% compared to Q4 2024, attributed to prior backorder catch-up effects. This dynamic is expected to impact growth rates in the first half of 2026.
International Sales Decline: International sales for Q4 2025 dropped by more than half to $600,000, primarily due to order timing in Canada. International sales represent only 8% of total sales, indicating limited global market penetration.
Noncash Inventory Write-Downs: Noncash inventory write-downs of $650,000 in Q3 and Q4 2025 suppressed gross margins, representing 5.9% of Q4 revenue and 2.4% of full-year revenue.
Operating Expense Increase: Operating expenses rose to $3 million in Q4 2025 from $2.2 million in Q4 2024, driven by higher G&A costs. Full-year operating expenses increased to $9.8 million in 2025 from $9.6 million in 2024.
Re-Tain Write-Down: A $2.7 million noncash write-down was taken for Re-Tain-related property, plant, and equipment in December 2025, reflecting a strategic shift away from this product line.
Manufacturing Capacity Constraints: Despite increasing manufacturing capacity to 4.6 million units in 2025, the company faced supply constraints that limited its ability to meet demand, impacting revenue growth.
Market Competition: The company competes against three of the largest animal health companies globally, which poses significant competitive pressures.
Limited International Market Share: International market opportunities remain underdeveloped, with the company capturing only a small portion of the global addressable market.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Growth in Manufacturing Capacity: The company plans to increase manufacturing capacity from 4.6 million units in 2025 to between 5 million and 6 million units per year through yield improvements and process optimizations. This is expected to meet demand for 2026 and 2027 while preparing for the next major capacity expansion.
Focus on First Defense Product Line: ImmuCell has shifted its strategy to focus exclusively on the First Defense product line, pausing investment in other products like the subclinical mastitis product. This allows the company to capitalize on the growing calf health market and improve manufacturing capabilities.
Market Opportunity and Expansion: The U.S. market for calf scours prevention is estimated at over $200 million, with international markets being at least five times larger. ImmuCell aims to increase its market share by targeting the 55% of calves that currently do not receive any scours prevention treatment.
Sales and Commercial Expansion: The company is increasing its sales capacity by hiring new sales managers and international market development leaders. Additional territory hires will be made based on market assessments. A new standardized sales approach has been implemented to scale commercial activities efficiently.
Product Demand and Pricing: The company expects continued growth in demand for First Defense products, driven by higher coverage rates and inventory normalization. The product is priced at approximately 2.5 times competitive alternatives, reflecting its superior efficacy.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the biggest challenges ahead for the company to achieve its goals in 2026 and 2027?
A:The company faces two main challenges: increasing yield and capacity through planned investments and operational improvements, and stepping up commercial activities to gain new customers. They aim to increase volume to 5-6 million units without major investments by improving floor planning, maintenance, and small equipment additions. Additionally, the commercial team is shifting from managing product allocations to proactive customer outreach to drive top-line growth.
Q:Will there be any additional Re-Tain write-downs in 2026?
A:The company does not anticipate any large write-downs for the assets formerly associated with Re-Tain. They are evaluating the best way to use the former Re-Tain plan and assets for a larger capacity expansion project. A modest salvage value of a couple of hundred thousand dollars has been booked for the written-down assets, but no significant write-downs are expected.
Q:How much of the 2025 revenue is considered recurring, and will this be the case in 2026 and 2027?
A:The company has not calculated churn or exact recurring revenue due to past supply constraints and backorder situations. However, customers have shown high loyalty and satisfaction with the product, even amidst price increases and supply issues. The company believes this loyalty will contribute to recurring revenue in the future.
Q:Review of Unclear Management Responses
A:The management avoided providing a direct answer regarding the exact calculation of recurring revenue for 2025, 2026, and 2027. They cited challenges in calculating churn due to supply constraints and backorder situations, offering only qualitative insights about customer loyalty and satisfaction instead of specific numerical data.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Boekhorst President
Canada sale
Conference Unaudited
Defense driver
Defense franchise
Defense manufacturing
asset inventory
backorder situation
comparison
customer
demand backorder
discussion
end
financials
good
income
increase
inventory write
loss improvement
loss share
margin improvement
noncash inventory
noncash write
order timing
product sale
remark
review
sale decrease
sale improvement
sale result
shift Tain
write down
ICCC Transcript
ImmuCell Corporation (ICCC) Q4 2025 Earnings Call Transcript
Unknown3-5
The earnings call presents mixed signals: improved gross margins and domestic sales growth are positive, but supply constraints, competition, and declining international sales offset this. The Q&A reveals management's evasiveness on recurring revenue, raising concerns. Despite operational improvements and no large future write-downs, the lack of guidance on recurring revenue and international market underdevelopment tempers optimism. The neutral sentiment reflects these balanced positives and negatives, with no strong catalysts to drive significant stock movement.
ImmuCell Corporation (ICCC) Q3 2025 Earnings Call Transcript
Unknown11-14
The earnings call presents a mixed picture: improved gross margins and domestic sales growth are positive, but international sales decline and regulatory delays pose risks. The Q&A highlights effective inventory management and customer engagement, but challenges in supply chain and competitive pressures remain. Despite financial improvements, the lack of new partnerships or strong guidance tempers optimism. Overall, the sentiment is neutral, as positives are balanced by uncertainties.
ImmuCell Corporation (ICCC) Q2 2025 Earnings Call Transcript
Positive8-15
The earnings call indicates strong financial performance with record revenue growth, improved EBITDA, and a better cash position. Challenges remain, such as FDA approval delays for Re-Tain and strategic partner needs, but management is addressing them. The reduction in backlog and net debt, coupled with a focus on First Defense expansion, are positive signs. The market is likely to react positively, considering the company's strategic initiatives and recent financial achievements, despite some uncertainties.
ImmuCell Corporation (ICCC) Q1 2025 Earnings Call Transcript
Positive5-15
The earnings call reflects strong financial performance, with record-high revenue growth and improved margins. Despite ongoing risks like potential contamination and senior management costs, the company has shown resilience with increased production capacity and reduced order backlog. The Q&A section did not reveal significant negative sentiment from analysts, and the optimistic guidance, coupled with operational improvements, suggests a positive stock price movement over the next two weeks.
ICCC Slides
ICCC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
